Treatment of lower urinary tract symptoms: Agents for intraprostatic injection.

Institute of Regenerative Medicine, Wake Forest University School of Medicine, and Department of Urology, Wake Forest Baptist Medical Center , Winston Salem, NC , USA.
Scandinavian journal of urology 01/2013; DOI: 10.3109/00365599.2012.752404
Source: PubMed

ABSTRACT Abstract When the currently available pharmacotherapeutic principles used for treatment of male lower urinary tract symptoms (LUTS) fail, transurethral resection of the prostate still remains the widely applied gold-standard therapy, since the majority of minimally invasive therapies have not achieved the same efficacy and/or lack an evidence base to support their routine use. Intraprostatic injection therapy, which probably is the oldest minimally invasive surgical treatment, has not been widely used, but recent reports of successful treatments with several new agents have renewed interest in this approach. Anhydrous ethanol still seems to be one of the most extensively studied injectables to date, but intraprostatic injection of botulinum toxin has received much recent attention, with regard to both its mechanism of action and efficacy. In addition, other agents such as NX-1207 and PRX302 have been reported to have promising effects. Injection therapy, using the transperineal, transrectal and transurethral routes for delivery of the active compounds, seems to be an effective minimally invasive surgical therapy for LUTS associated with benign prostatic hyperplasia (BPH). However, further studies on mechanisms of action of the novel agents used, and controlled clinical trials documenting their efficacy and side-effects (which are largely lacking), are needed before their place in the treatment of BPH/LUTS can be properly assessed.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study is to review and discuss recently published (2013-2014) experimental and clinical studies of intraprostatic injection therapy as an alternative treatment of lower urinary tract symptoms (LUTS).
    Current Opinion in Urology 10/2014; DOI:10.1097/MOU.0000000000000122 · 2.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Transurethral dilatation of the prostate (TUDP) with a spherical balloon catheter is a traditional treatment to benign prostatic hyperplasia (BPH) patients. However, TUDP has been abandoned in clinical application because of its unsatisfying treatment benefit and severe complications. In this study, we redesigned an improved TUDP surgery, named transurethral split of the prostate (TUSP), by replacing the spherical balloon with a columnar balloon. To evaluate the clinical therapeutic effect, we compared the lower urinary tract symptoms (LUTS) of BPH patients after TUSP treatment and analyzed the urethra through CT films. Animal experiments were performed on aged dogs to investigate the urine function and electromyography (EMG) changes. Histopathology was used to evaluate the inflammation and injury. Additionally, collagen content was detected by Trichrome Masson. TUSP attenuated LUTS and reconstructed urethra in BPH patients. The attenuation of LUTS was reflected in terms of LUTS parameters such as Qmax, post-void residual urine volume (PVR), quality of life (QOL) score and International Prostate Symptom Score (IPSS). TUSP expanded the urethra in experimental dogs by splitting the prostate tissues and decreasing the collagen content, with maintenance of normal urinary function and EMG characteristics. The successful clinical application of TUSP with significant therapeutic effect and limited complications made TUSP an ideal choice for the BPH patients.
    Journal of endourology / Endourological Society 10/2014; 29(3). DOI:10.1089/end.2014.0207 · 2.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The authors have conducted a study to evaluate the mechanism and effectiveness of transurethral balloon dilation of the prostate for the management of bladder outlet obstruction. The patients selected have moderate to significant obstructive voiding symptoms, had moderately enlarged prostates (avg. 48 cc) and underwent a single session of transurethral balloon dilation of the prostate. The patients appeared to have good outcomes based on pre and postoperative evaluation of their QOL and IPSS scores and the results were relatively durable. CT scans in some patients confirmed anterior disruption of the prostate with resultant sustained defect anteriorly in some. The authors conclude that the use of a columnar balloon is superior to the use of a spherical balloon in achieving this clinical outcome; however, there are no direct comparisons in this patient population between the use of a spherical balloon and the use of a columnar balloon. Review of the literature from the 1980s and 1990s, when transurethral balloon dilation of the prostate was introduced and in relatively widespread use, showed conflicting but generally disappointing results in terms of the durability of clinical outcomes.1,2,4 A review of the literature reveals that balloons similar to the one described in this study were in use at that time.3,4 It is possible that the differentiating aspect of the procedure described in this study was that the balloon was left fully inflated for five to six hours after the procedure. It is possible that this expansion and compression of the prostate could lead to some vascular compromise of the tissue and perhaps result in more scar tissue formation and decreased collagen deposition as well as some atrophy of the glandular tissue itself. If the proposed mechanism of action is correct, very similar results could theoretically be obtained by simple transurethral incision of the prostate and capsule anteriorly.
    Journal of endourology / Endourological Society 12/2014; DOI:10.1089/end.2014.0825 · 2.10 Impact Factor